This company listing is no longer active
Annexin Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Annexin Pharmaceuticals has a total shareholder equity of SEK6.3M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK11.8M and SEK5.5M respectively.
Key information
0%
Debt to equity ratio
SEK 0
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 7.87m |
| Equity | SEK 6.35m |
| Total liabilities | SEK 5.47m |
| Total assets | SEK 11.81m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ANNX BTA's short term assets (SEK10.0M) exceed its short term liabilities (SEK5.5M).
Long Term Liabilities: ANNX BTA's short term assets (SEK10.0M) exceed its long term liabilities (SEK1,000.0).
Debt to Equity History and Analysis
Debt Level: ANNX BTA is debt free.
Reducing Debt: ANNX BTA has no debt compared to 5 years ago when its debt to equity ratio was 1.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANNX BTA has sufficient cash runway for 2 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ANNX BTA is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.